This is not the most recent version of the article. View current version (9 DEC 2013)

Intervention Protocol

Immunosuppressive drug therapy for preventing rejection following lung transplantation in cystic fibrosis

  1. Ian J Saldanha1,*,
  2. Naomi A Mckoy2,
  3. Karen A. Robinson1

Editorial Group: Cochrane Cystic Fibrosis and Genetic Disorders Group

Published Online: 9 NOV 2011

Assessed as up-to-date: 19 SEP 2011

DOI: 10.1002/14651858.CD009421


How to Cite

Saldanha IJ, Mckoy NA, Robinson KA. Immunosuppressive drug therapy for preventing rejection following lung transplantation in cystic fibrosis (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 11. Art. No.: CD009421. DOI: 10.1002/14651858.CD009421.

Author Information

  1. 1

    Johns Hopkins University, Department of Medicine, Baltimore, MD, USA

  2. 2

    Human Genome Sciences, Inc., SSM Microbial Upstream Common Use Production, Rockville, Maryland, USA

*Ian J Saldanha, Department of Medicine, Johns Hopkins University, 1830 E. Monument St. Suite 8047-A, Baltimore, MD, 21287, USA. isaldanh@jhsph.edu.

Publication History

  1. Publication Status: New
  2. Published Online: 9 NOV 2011

SEARCH

This is not the most recent version of the article. View current version (09 DEC 2013)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The objective of this review is to assess the effects of immunosuppressive drug therapy to prevent rejection following lung transplantation in patients with CF. In particular, this review aims to assess the effects of individual drugs or combinations of individual drugs compared to placebo or other individual drugs or combinations of individual drugs.